Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析

◆英語タイトル:Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1331
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥16,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥32,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥48,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Ultragenyx Pharmaceutical Inc (RARE) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ultragenyx Pharmaceutical Inc (Ultragenyx) develops novel therapeutics for rare and ultra-rare genetic diseases. It has two marketed products, Mepsevii (vestronidase alfa) is approved for the treatment of adults and children with Mucopolysaccharidosis (MPS) VII (Sly syndrome) and Crysvita (burosumab), a fully human monoclonal antibody for the treatment of X-linked hypophosphatemia (XLH). Its pipeline includes Crysvita for the treatment of tumor-induced osteomalacia (TIO); DTX401 for the treatment of patients with glycogen storage disease type Ia, or GSDIa; UX007 for the treatment of LC-FAOD and DTX301 for the treatment of ornithine transcarbamylase. It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.

Ultragenyx Pharmaceutical Inc Key Recent Developments

Apr 01,2020: REGENXBIO and Ultragenyx announce new license agreement for use of NAV technology platform for the treatment of Rare Metabolic Disorder
Mar 31,2020: Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing …
Mar 31,2020: Regenxbio teams up with Ultragenyx in gene therapy for rare metabolic disorder
Mar 31,2020: REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Ultragenyx Pharmaceutical Inc – Key Facts
Ultragenyx Pharmaceutical Inc – Key Employees
Ultragenyx Pharmaceutical Inc – Key Employee Biographies
Ultragenyx Pharmaceutical Inc – Major Products and Services
Ultragenyx Pharmaceutical Inc – History
Ultragenyx Pharmaceutical Inc – Company Statement
Ultragenyx Pharmaceutical Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Ultragenyx Pharmaceutical Inc – Business Description
Product Category: Crysvita
Overview
Performance
Product Category: Mepsevii
Overview
Performance
Product Category: UX007
Overview
Performance
Geographical Segment: All other
Performance
Geographical Segment: Europe
Performance
Geographical Segment: US
Performance
R&D Overview
Ultragenyx Pharmaceutical Inc – Corporate Strategy
Ultragenyx Pharmaceutical Inc – SWOT Analysis
SWOT Analysis – Overview
Ultragenyx Pharmaceutical Inc – Strengths
Ultragenyx Pharmaceutical Inc – Weaknesses
Ultragenyx Pharmaceutical Inc – Opportunities
Ultragenyx Pharmaceutical Inc – Threats
Ultragenyx Pharmaceutical Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 01, 2020: REGENXBIO and Ultragenyx announce new license agreement for use of NAV technology platform for the treatment of Rare Metabolic Disorder
Mar 03, 2020: Ultragenyx announces planned transition of Chief Financial Officer
Feb 13, 2020: Ultragenyx reports fourth quarter and full year 2019 financial results and corporate update
Jan 13, 2020: Ultragenyx reports preliminary 2019 revenue and provides 2020 Crysvita revenue guidance
Nov 05, 2019: Ultragenyx reports third quarter 2019 financial results and corporate update
Aug 01, 2019: Ultragenyx reports second quarter 2019 financial results and corporate update
Jun 17, 2019: Ultragenyx expands leadership team and promotes Erik Harris to chief commercial officer
May 06, 2019: Ultragenyx reports first quarter 2019 financial results and corporate update
Feb 19, 2019: Ultragenyx announces fourth quarter and full year 2018 financial results
Feb 04, 2019: Ultragenyx Pharmaceutical names Shehnaaz Suliman, M.D., to Board of Directors
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ultragenyx Pharmaceutical Inc, Key Facts
Ultragenyx Pharmaceutical Inc, Key Employees
Ultragenyx Pharmaceutical Inc, Key Employee Biographies
Ultragenyx Pharmaceutical Inc, Major Products and Services
Ultragenyx Pharmaceutical Inc, History
Ultragenyx Pharmaceutical Inc, Subsidiaries
Ultragenyx Pharmaceutical Inc, Key Competitors
Ultragenyx Pharmaceutical Inc, Ratios based on current share price
Ultragenyx Pharmaceutical Inc, Annual Ratios
Ultragenyx Pharmaceutical Inc, Annual Ratios (Cont...1)
Ultragenyx Pharmaceutical Inc, Interim Ratios
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Ultragenyx Pharmaceutical Inc, Performance Chart (2015 - 2019)
Ultragenyx Pharmaceutical Inc, Ratio Charts
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hospitality Properties Trust:企業のM&A・事業提携・投資動向
    Hospitality Properties Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hospitality Properties Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Witte Molen N.V.:企業の戦略・SWOT・財務情報
    Witte Molen N.V. - Strategy, SWOT and Corporate Finance Report Summary Witte Molen N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • CardioFocus Inc-医療機器分野:企業M&A・提携分析
    Summary CardioFocus Inc (CardioFocus) is a medical device company that manufactures and distributes investigating disposable fiber optic catheters and endoscopic products. The company provides cardiofocus endoscopic ablation system that consists of balloon catheter, deflectable sheath introducer, en …
  • Queen Mary University of London-製薬・医療分野:企業M&A・提携分析
    Summary Queen Mary University of London (Queen Mary), formerly Queen Mary and Westfield College, a subsidiary of University of London, is a research university that offers undergraduate and postgraduate education; and research programs. The university provides graduation and education services in ar …
  • Siemens Healthcare GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Siemens Healthcare GmbH d/b/a Siemens Healthineers, a subsidiary of Siemens AG, is a global medical device company that designs, develops, manufactures and distributes medical devices and technologies for diagnostic markets. Its major products include healthcare IT and medical infrastructure …
  • Canadian Pacific Railway Limited (CP):企業の財務・戦略的SWOT分析
    Canadian Pacific Railway Limited (CP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Dominion Energy Inc (D):電力:M&Aディール及び事業提携情報
    Summary Dominion Energy, Inc. (Dominion), formerly Dominion Resources, Inc., is a producer and transporter of energy. It carries out the generation, transmission and distribution of electricity; transmission, distribution, storage and processing of gas; and LNG import and storage activities. The com …
  • Pedernales Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Pedernales Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Apotex Inc-製薬・医療分野:企業M&A・提携分析
    Summary Apotex Inc (Apotex) produces and markets a wide range of generic pharmaceuticals. It also undertakes the research, development, manufacture and distribution of non-prescription and private label medicines, fine chemicals and disposable plastics for medical use. The company has research and d …
  • Boralex Inc (BLX):電力:M&Aディール及び事業提携情報
    Summary Boralex Inc (Boralex) is a renewable energy company. It develops, builds, and operates renewable energy power facilities. The company’s asset portfolio includes wind, hydro, thermal, and solar projects. Boralex also has interests in various projects under development stages. Under long-term …
  • Advantest Corporation:企業の戦略・SWOT・財務分析
    Advantest Corporation - Strategy, SWOT and Corporate Finance Report Summary Advantest Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Xtract Resources Plc (XTR):企業の財務・戦略的SWOT分析
    Summary Xtract Resources Plc (Xtract Resources), formerly Xtract Energy plc is a mining and mineral exploration and development company that offers mineral resources. The company acquires, explores, manages, operates, produces, mines, extracts, and develops gold and mineral resource deposit properti …
  • Hemostemix Inc (HEM):製薬・医療:M&Aディール及び事業提携情報
    Summary Hemostemix Inc (Hemostemix), formerly Theravitae Inc, is a biotechnology company that develops, manufactures and commercializes proprietary autologous cell therapy for the treatment of ischemic diseases. The company’s clinical-stage candidate includes ACP-01, an autologous cell therapy for t …
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196)-医療機器分野:企業M&A・提携分析
    Summary Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products include metabolism …
  • Astrazeneca Pharma India Ltd (ASTRAZEN):企業の財務・戦略的SWOT分析
    Summary AstraZeneca Pharma India Ltd (AstraZeneca), is a biopharmaceutical company that discovers, develops, and commercializes medicines. The company offers products in the therapeutic areas including cardiovascular and metabolic diseases, respiratory, maternal healthcare, oncology, infection, neur …
  • Engie SA (ENGI):企業の財務・戦略的SWOT分析
    Engie SA (ENGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Opthea Ltd (OPT):企業の財務・戦略的SWOT分析
    Summary Opthea Ltd (Opthea), formerly Circadian Technologies Ltd, is a biotechnology company that develops novel biologic therapy for the treatment of eye diseases. The company carries out research and development of angiogenesis and vascular leakage-based treatments for cancer concentrating on vasc …
  • Reitmans (Canada) Limited (RET.A):企業の財務・戦略的SWOT分析
    Reitmans (Canada) Limited (RET.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Discovery Holdings Limited (DSY):企業の財務・戦略的SWOT分析
    Discovery Holdings Limited (DSY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Karur Vysya Bank Ltd:企業の戦略・SWOT・財務情報
    Karur Vysya Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Karur Vysya Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆